Safety Study of High Dose Temozolomide to Treat Relapsed/Refractory Central Nervous System (CNS) Malignancy

Inclusion Criteria:

Patients or their health care proxies must be able to provide consent to participate in this trial.

Patients must have one of the following diagnoses which has not responded or recurred following at least one prior chemotherapy regimen or radiation therapy:

anaplastic astrocytoma, glioblastoma multiforme or oligodendroglioma
primary CNS lymphoma
malignant disease metastatic to the CNS

Patients must be candidates for high dose chemotherapy and autologous stem cell transplant according to the following criteria:

Patients must be between the ages of 18 and 70 years (inclusive)
Patients must have a left ventricular ejection fraction greater than or equal to 45% by MUGA or echocardiogram
Patients must have adequate pulmonary function with FEV1, FVC and DLCO greater than or equal to 50% of predicted
Patients must have serum direct bilirubin less than or equal to 2.0 mg/dl and transaminases less than or equal to 3x institutional upper limit of normal
Patients must have serum creatinine less than or equal to 2 mg/dl with creatinine clearance greater than or equal to 60 ml/min (either calculated or measured)
Patients must have an ECOG performance status between 0 and 2
Patients must be at least 4 weeks from last cytoreductive chemotherapy.
Expected survival of at least 3 months

Exclusion Criteria:

Patients with uncontrolled metastatic disease outside of the CNS which would itself, in the investigator's opinion, limit survival to less than 6 months
Patients with uncontrolled seizures are ineligible.
Patients with a history of myocardial infarction within the preceding 6 months, significant arrhythmia within the preceding 3 months, or uncontrolled hypertension or congestive heart failure are ineligible.
Patients with unstable angina are ineligible.
Pregnant or lactating women are ineligible.
Male and female patients who do not agree to practice approved methods of birth control for the duration of the study are ineligible.
Patients with uncontrolled, active infection are ineligible.
Patients infected with HIV are ineligible.